Our translational human microbiome research program focuses on gastrointestinal and airway microbiome interactions with host immunity that promote or prevent development/maintenance of chronic inflammatory disease. Taking a “populations to molecules” approach we leverage the microbiome to determine the origins of childhood allergy and asthma and the early life molecular and cellular drivers of immune dysfunction that lead to childhood disease development. We also leverage human population studies and clinical trials to gain insights into the role of the gut microbiome in inflammatory bowel disease. Our studies allow us to develop rationally designed microbial therapeutics, leading to the founding of Siolta Therapeutics which is currently testing a lead product developed in our lab for the prevention of childhood allergy and asthma.
Microbiome expands the genetic and functional capacity of its human host. Susan Lynch explains that human microbiome develops early in life and that gut microbes shape immune function and relate to disease outcomes in childhood. She also explores next-generation microbiome therapeutics and research. Recorded on 11/07/2019. (#35240)